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Introduction
Coronary artery disease (CAD) is the leading cause of mortality and morbidity worldwide [1] . In the clinical prognosis of CAD, the complexity and severity of atherosclerosis is as important as the resistance of the heart to ischemia. Myocardial tissue with a sufficiently rich collateral network is more resistant to ischemia. In patients with occluded coronary arteries, the signs and symptoms may be milder. In patients with chronic stable CAD, well-developed coronary collateral circulation (CCC) is known to reduce longterm mortality [2] . The development of CCC as a response to severe coronary stenosis may vary between individuals. Today, factors that cause these differences are not fully revealed.
Two mechanisms, namely angiogenesis and arteriogenesis, are known to play a role in coronary collateral development. Angiogenesis is the process of growth, expansion and restructuring of primitive vessels to form a complex and mature vascular network [2, 3] .
Arteriogenesis is the conversion of pre-existing collateral arterioles into muscular collateral arteries. Angiopoietins are one of the angiogenetic regulators involved in the angiogenesis cascade. Angiopoietins modulate vascular development and restructuring during angiogenesis and inflammation [3] . Angiopoietin-1 (Ang-1) released from endothelium plays an important role in vascular stabilization and vascular maturation. It demonstrates its VEGF-related inflammation-reducing effect by inhibiting the release of adhesion molecules [4] .
Angiopoietin-2 (Ang-2) released from Weibel-Palade bodies is a competitive inhibitor of Ang-1 and inhibits the effect of Ang-1 by binding to Tie-2 receptors. It makes the endothelium susceptible to inflammatory agents and facilitates VEGF-mediated angiogenesis [5] [6] [7] .
Calprotectin, a member of the S100 family, is a heterodimeric calcium-binding complex protein with two subunits, S100A8 and S100A9 is a large leukocyte (monocyte / macrophage) protein that makes up to half of the cytosolic protein in neutrophil granulocytes.
It is released by neutrophils and monocytes during the interaction of inflammation-activated endothelium and monocytes. It binds to endothelial cells and modulates the trans-endothelial transport of leukocytes [8, 9] . There are no studies on the role of serum calprotectin in collateral vascular development.
For patients who cannot have coronary artery revascularization, especially those who do not benefit from conventional therapy, new therapeutic approaches are needed to achieve CCC formation. For this purpose, we investigated the relationship between serum calprotectin, Ang-1 and Ang-2 levels and coronary collateral circulation in patients with severe stenosis in at least one of the coronary arteries.
Methods

Study design and population
This cross-sectional, prospective study was carried out at the Department of Cardiology, Bozok University Faculty of Medicine, Turkey. 147 consecutive patients who underwent coronary angiography from June 2016 to January 2019 and whose coronary angiography showed more than 90% stenosis in at least one coronary artery were included in the study. Patients with a medical history of previous coronary revascularization, acute coronary syndrome in the last six months, moderate and severe valvular disease, pericardial disease, congenital heart disease, cardiomyopathy diagnosis, acute infection or chronic inflammatory disease, renal (estimated glomerular filtration rate <50 mL/min per 1.73 m 2 ) and liver dysfunction (transaminase levels three times higher than the upper limit) were excluded from the study. In addition, patients who use antihypertensive, antihyperlipidemic, antiplatelet, and anticoagulant drugs were excluded from the study. The study protocol approved by the local ethics committee (Approval no: 11/05-04.05.2016) was explained to the patients and patients who accepted the protocol were included in the study upon reception of their written consent.
The patients were examined physically and demographic characteristics, cardiovascular risk factors and drugs used were recorded. Transthoracic echocardiographic examination was performed with Philips Affiniti 50 echocardiography device (Philips Healthcare, the Netherlands) according to the recommendations of American Society of Echocardiography. Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson method. Patients with fasting blood glucose levels of 126 mg/dl or higher or taking oral anti-diabetic medication and insulin were considered as diabetic, patients with systolic blood pressure of 140 mmHg or higher, diastolic blood pressure of 90 mmHg or higher or using antihypertensive drugs were considered hypertensive, and patients with total cholesterol of 200 mg/dL or higher or receiving hyperlipidemia treatment were considered as hyperlipidemia.
Smoking was defined as current smoking. Body mass index (BMI) was calculated by dividing body weight by the square of the neck (kg/m²).
Laboratory tests
Fasting venous blood samples were collected in 5 mL BD Vacutainer SST II advance (Becton, Dickinson and Company Franklin Lakes, NJ, USA) in the morning after acceptance to the Cardiology Department and centrifuged at 1300 × g for 10 min after completion of clotting. These separated sera were stored at -80°C until measurement. Serum calprotectin, serum Ang-1 and Ang-2 levels were analyzed using the Human ELISA kit (Sunlong Biotech Co., Ltd China). The calprotectin, Ang-1 and 2 values were expressed in ng/ml. In addition, the complete blood count was measured on the Sysmex XN-1000 analyzer while C-Reactive Protein (CRP), lipid profile, liver and kidney function parameters were measured in Abbott Architect C 4100 auto-analyser.
Coronary Angiography and Coronary Collateral Scoring
Coronary angiography was performed through the right femoral arterial route using standard Judkins method. Coronary arteries were visualized using cranial and caudal angles in the right and left oblique plane. Iopromide (Ultravist 370, Schering AG, Berlin, Germany) was used as the contrast agent for coronary angiography. Coronary angiography images of the patients were evaluated by two experienced cardiologists who were not familiar with their clinical features and laboratory values. Inter-observer agreement of Rentrop collateral grades was evaluated with a random sample of 30 coronary angiograms (κ=0.621; P<0.001). Stenosis and lesion length in the coronary arteries were calculated quantitatively using the 'Digital Imaging and Communications in Medicine' (DICOM) program. CCC was evaluated using the Cohen-Rentrop score and was classified as stage 0-3 according to contrast agent involvement in the occluded artery [10] . This classification is defined as follows; score 0: no significant collateral circulation, score 1: collateral circulation to the lateral branches without reaching the epicardial artery, score 2: partial filling of the epicardial artery, score 3: full filling of the epicardial artery. For all patients, SYNTAX scores which are used to evaluate extent and complexity of CAD were calculated. For the calculation of SYNTAX score, the web-based program on www.syntaxscore.com was used [11] . As a second method, the severity of coronary lesions was also calculated using the Gensini score [12] . The patients were divided into two groups according to Cohen-Rentrop score, with 79 patients with poor coronary collateral vascularization (Cohen-Rentrop score 0-1) and 68 patients with good coronary collateral vascularization (Cohen-Rentrop score 2-3).
Statistical analyses
Statistical analysis was performed using SPSS 21 (Statistical Package for Social Sciences) software. The suitability of data for normal distribution was evaluated by Kolmogorov-Smirnov test in the sample size of more than 30 and Shapiro-Wilkis test in the group of less than 30. The descriptive statistics of continuous variables were expressed as mean (standard deviation) or median (minimum-maximum). The data that fit the normal distribution were evaluated with parametric tests and the data that did not fit were evaluated with non-parametric tests. Categorical variables were evaluated by Pearson chi-square or
Fisher exact chi-square test, and continuous variables were evaluated by Student's T-test or
Mann-Whitney U test. Kruskal Wallis test was used for the analysis of multiple groups. For correlation analysis, Pearson or Spearman correlation tests were used according to the distribution of parameters. The parameters were evaluated by univariate logistic regression analysis in order to show poor coronary collateral development. Parameters with p ≤0.2 in univariate logistic regression analysis were reevaluated by multivariate logistic regression analysis. Values were expressed as mean (standard deviation). In all evaluations, p <0.05 was considered statistically significant.
Results
A total of 248 patients were evaluated. Ten patients were excluded from the study for a history of acute coronary syndrome in the last month, 8 patients for a history of coronary artery bypass graft operation, 13 patients for a history of percutaneous coronary intervention, 50 patients for non-compliance with the inclusion criteria, 10 patients for moderate-severe heart valve disease, 6 patients for renal failure, and 4 patients for acute infection and chronic inflammatory disease. The remaining 147 patients were included in the study (100 females, 47 males). Among 147 subjects, 79 patients had poor CCC (mean age: 62 (9) years) and 68 patients had good CCC (mean age: 60 (7) years). There was no difference between the groups in terms of age, gender, BMI, heart rate, diabetes mellitus, hyperlipidemia, hypertension and smoking ( Table 1) . Fasting blood glucose, creatinine, alanine aminotransferase, aspartate aminotransferase, albumin, total cholesterol, and triglycerides were similar in both groups.
Leucocytes (p<0.01), low-density lipoprotein cholesterol (p<0.05), lymphocyte count (p<0.01), and CRP (p <0.01) were significantly higher in patients with poor CCC than in those with good CCC. High-density lipoprotein cholesterol levels were significantly lower in poor CCC group than in good CCC group (p <0.005). There was no statistically significant difference between the echocardiographic data of the groups (p ≥0.05 for all) ( Table 2) .
There was no statistically significant difference between the groups in terms of coronary angiography data such as number of affected vessels, percentage of lesion vessel stenosis, involved vessel, lesion length, lesion location, lesion type, Gensini and SYNTAX scores (p ≥0.05 for all) ( Table 3) .
Median serum calprotectin level of the poor CCC group was 39.1% higher than that of the good CCC group (p<0.01), similarly median Ang-1 level of the poor CCC group was 22.0% higher than that of the good CCC group (p<0.001). However median serum Ang-2 level of the poor CCC was 19.9% lower than that of the good CCC group (p <0.01) ( Table 3) .
In correlation analysis, CRP values were positively correlated with calprotectin (r = 0.359; p <0.001) (Figure 1 ). There were no statistically significant correlations between CRP and Ang-1 or Ang-2.
In multivariate analysis including age (β:-0.094, p=0.274), calprotectin (β:-0.185, p<0.05), Ang-1 (β:-0.276, p<0.005), Ang-2 (β:0.102, p=0.226), Gensini score (β:0,019 p=0.841) and SYNTAX score (β:-0.175, p=0.058), it was found that only calprotectin and Ang-1 were found to be an independent parameter implying the presence of good or poor CCC (R=0,426, p<0.001).
Discussion
The current study showed that poor CCC patients were detected to have lower Ang-2 and higher calprotectin and Ang-1 levels compared to patients with good CCC. Elevated calprotectin, which is an inflammatory marker, and a low Ang-2, which plays a role in arteriogenesis, have suggested that these molecules may be important for the presence of CCC.
The current studies show that the key role of angiopoietins in angiogenesis and arteriogenesis has been shown in experimental studies [4] . In addition, growth factors released from inflammatory cells, e.g. monocytes, that attack the ischemic region in angiogenesis and arteriogenesis are also involved in this process [1, 3, 13, 14] . Some cytokines initiate an inflammatory response by activating transcription factors. These stimuli activate endothelium and pre-synthesized and stored molecules such as Von-Willebrand factor, P-selectin, CD63, IL-8, endothelin-1, tissue plasminogen activator and Ang-2 are released in seconds [13] . All of these molecules are involved in the control of rapid endothelial response, hemostasis, inflammation, hemodynamic adaptation and vascular permeability.
Calprotectin is a newly identified cytokine that can be detected in the cytoplasm of healthy individuals. It is found to increase locally in tissue trauma and inflammation.
Calprotectin, released from activated granulocytes and macrophages during inflammation, creates a pro-inflammatory effect [5, 15] . Serum calprotectin levels were found to be increased in CAD patients compared to healthy subjects. In addition, this increase has been shown to be associated with cardiovascular mortality [15, 16] . Moreover, it has been shown that mortality due to all causes is increased in patients without CAD but with high serum calprotectin levels [17] . Similarly, in our study, CRP values, which can be defined as markers of inflammation, were higher in the poor CCC group. In addition, CRP values showed a positive correlation with calprotectin. Although inflammation is a basic defense mechanism and the body's reaction, the continuous elevation of some inflammatory biomarkers has a key role in the development and prognosis of cardiovascular diseases [18] . It has been reported that calprotectin facilitates the formation of Reactive oxygen species (ROS) by activating NADPH oxidase, and plays a role in the pathogenesis of atherosclerosis by interacting with RAGE and the toll-like receptor and accelerating the signaling pathway [13] . In a study by Katashima et al., serum calprotectin levels were found to be high in acute myocardial infarction (AMI) patients. Additionally, the peak calprotectin levels among AMI patients were positively related to peak leukocyte and neutrophil counts along with peak CK-MB and CRP levels [19] .
In a study conducted by Jensen et al. [20] with 41 ST segment elevated myocardial infarction (STEMI) patients treated with successful percutaneous coronary intervention (STEMI), calprotectin levels were significantly higher in 13 STEMI patients who died after a mean follow-up of 12 months compared to surviving STEMI patients (0.209 versus 0.174 mg/L; p <0.001). Calprotectin was associated with adverse clinical outcome in patients with clinically suspected chest pain. In another study of long-term follow-up of approximately 84 months of 871 consecutive patients with suspected acute coronary syndrome, calprotectin level was associated with total mortality (hazard ratio, 1.94; 95% CI 1.42-2.66; p = <0.001) and recurrent AMI (hazard ratio, 1.60; 95% CI 1.06-2.41; p = 0.024) (21) . Thus, the prognostic significance of calprotectin was emphasized by these studies [20, 21] . In our study, since patients with acute coronary syndrome were excluded, no comparison was possible; however, high serum calprotectin levels were of interest in patients with poor CCC.
Several studies have shown that inflammatory process and growth factors play an important role in the development of CCC in the presence of myocardial ischemia [13, [22] [23] [24] [25] [26] . Some biomarkers may be useful for demonstrating the diversity of CCC development. As previously mentioned, calprotectin, Ang-1 and Ang-2 are biomarkers involved in angiogenesis and inflammation. Calprotectin is known to increase in inflammatory events, and inflammation plays an important role in the onset and progression of atherosclerosis.
Angiopoietin-1 and angiopoietin-2 are molecules involved in vascular maturation and angiogenesis. In our study, calprotectin and Ang-1 levels were lower and Ang-2 levels were higher in the patient group with good collateral development. All of these points to the presence of more intensive angiogenesis in the heart with good collateral circulation.
In the literature, few studies examining the relationship between Ang-1 levels and CCC development have shown that there is a relationship between elevated plasma Ang-1 levels and CCC development, and that those with high plasma Ang-1 levels and low plasma Ang-2 levels have worse CCC development [4] . In a case-control study of 695 acute coronary syndrome cases and 690 healthy subjects, Ang-2 surfaced as a biomarker of AMI [24] . In our study, calprotectin and Ang-1 values were low and Ang-2 values were high in patients with good CCC in accordance with the literature. Furthermore, in multivariate analysis, calprotectin and Ang-1 were independently associated with the presence of poor CCC in the study population. What makes our study more important is that this relationship was demonstrated in patients with stable CAD. Because it is known that calprotectin values are higher in patients with acute coronary syndrome [20, 21] . It is suggested that Ang-1 can prevent remodeling by providing vascular integrity and can correct the impaired balance by shifting Ang-1 / Ang-2 ratio to Ang-1 side. Furthermore, high levels of calprotectin without acute coronary syndrome suggest that a subclinical inflammation in stable CAD may have a negative effect on CCC.
In a study conducted by Gok et al., it was found that higher CRP had positive correlation with poor CCC along with lower ischemia modified albumin in the patient with stable CAD [27] . Our findings also confirmed this result that CRP was significantly higher in the poor CCC group and additionally, CRP was statistically significant with serum calprotectin. Most likely this was related to high inflammatory status of the patients with poor CCC. The study by Sen et al. also underlined the relation between CRP and poor CCC development. It was reported that higher CRP was related to higher adverse clinical events and higher probability for presence of non-infarct related chronic total occlusion in the patient with acute STEMI [28]. All these findings may reflect the continuous process of CCC development.
Although cardiovascular risk factors have been shown to have negative effects on the development of CCC [5] , in our study, there was no statistically significant difference between the two groups in terms of classical risk factors other than high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. This may be due to the low number of patients and the exclusion of patients who use medication for risk factors. Long-term complex mechanisms may exist between CCC and serum calprotectin and angiopoietins. If the relationship between these markers and CCC is elucidated, high-risk patients can be detected earlier, and aggressive treatment can be initiated. In addition, if these mechanisms are revealed, new treatment strategies can be developed for high-risk CAD patients.
Limitations:
The most important limiting factor of our study was the small number of patients. This may have prevented the identification of additional risk factors that may affect the development of CCC. Another limiting factor of the study was the detection of coronary collateral circulation by coronary angiography. As is known, collateral vessels having a diameter of at least 100 micrometers can be angiographically visualized, while collateral vessels of smaller diameter cannot be detected angiographically. Therefore, patients who are thought to have an inadequate CCC network may have collateral vessels that cannot be detected angiographically. In the study, we excluded any patients under treatments with antihypertensive, antihyperlipidemic, antiplatelet, and anticoagulant drugs which may have effect on development of CCC. However it may have a potential limitation since it may not reflect real-life setting. Thus, the results may not be applied to the general population. 
